Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
1 paper1 finding
- Human trial1
Associations
1Semaglutide
downin humans1HR 0.74
1 study
Semaglutide
downin humans1HR 0.74
Semaglutide lowers the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in humans (HR 0.74, 95% CI 0.58 to 0.95).
“The primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and in 146 of 1649 patients (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95; P<0.001 for noninferiority).”
Human trialtype 2 diabetes at high cardiovascular risk0.5 mg or 1.0 mg104 weeksn = 3,297
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
The New England journal of medicine15 Sep 2016
Latest
6 in 12 monthsAmerican Heart Journal
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
Trial in 7,076 peopleCardiovascular disease
JAMA Cardiology
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial
Randomised trial in 17,604 peopleSemaglutide
AHA Scientific Sessions 2025 Abstract
Efficacy and Safety of Semaglutide According to Frailty Status in the SELECT Trial
Trial in peopleInterventions
AHA Scientific Sessions 2025 Abstract
Beyond Glycemic Control: Cardiovascular Benefits of GLP-1 Receptor Agonists in Type 2 Diabetes
ReviewInterventions
Circulation
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Randomised trial in 10,142 peopleCanagliflozin
The New England Journal of Medicine
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Randomised trial in 3,297 peopleSemaglutide